NBIX News and Press, Neurocrine Biosciences Inc. From 05/03/23

Neurocrine Biosciences Reports First Quarter 2023 Financial Results PR Newswire INGREZZA ® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 - $1....

Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference PR Newswire SAN DIEGO , May 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2023 Healthcare Conferenc...

2023-05-02 13:07:54 ET Neurocrine Biosciences ( NASDAQ: NBIX ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is $0.74 (+146.7% Y/Y) and the consensus Revenue Estimate is $409.07M (+31.7% Y/Y). Over th...

Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week PR Newswire Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and nearly seven out of 10 people living with the condition have not yet ...

2023-04-24 19:30:47 ET Summary Neurocrine Biosciences, Inc. results from both registrational studies, using Crinecerfont for the treatment of adults and pediatric patients with Congenital Adrenal Hyperplasia, are expected in the 2nd half of 2023. A PDUFA date of August 20, 2023, h...

2023-04-22 09:32:44 ET Summary “Best” in comparison to Risk~Reward tradeoffs of an equity investor’s today alternatives as seen by “institutional investor” experienced evaluators and Market-making professional traders. Definitions: Reward = profi...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results PR Newswire Conference Call and Webcast Scheduled for Wednesday, May 3 SAN DIEGO , April 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) ...

2023-03-30 10:49:34 ET Canaccord Genuity has upgraded Neurocrine Biosciences ( NASDAQ: NBIX ) to buy from hold saying that while the stock is down considerable year to date, the firm believes it can beat 2023 outlook on Ingrezza sales. The firm raised its price target to $...

2023-03-29 06:54:35 ET Neurocrine Biosciences ( NASDAQ: NBIX ) announced late Tuesday that Teva Pharmaceutical  ( NYSE: TEVA ) has agreed to delay the launch of generic versions of its tardive dyskinesia therapy Ingrezza, resolving a patent dispute between the two. ...